Brian Rini, MD, FACP, discusses recent practice-changing findings in advanced RCC, including comparisons with historical data, considerations for choosing treatment, and adverse event management.
In this downloadable slideset, Brian Rini, MD, FACP discusses recent practice-changing findings in advanced RCC and how to select optimal treatment for individual patients.
Cabozantinib is changing the paradigm in RCC. How should it be integrated into your clinical practice?
New agents and anticipated new approvals are substantially changing the treatment landscape for RCC. In this activity, I discuss my perspective on using current and emerging treatment options in the clinic.
With the plethora of new drugs, combination regimens, and approaches for RCC, selecting the right agent can be challenging for clinicians.
This interactive treatment decision aid will let you compare your choice of therapy for patients with advanced RCC with expert recommendations from Thomas E. Hutson, DO, PharmD, FACP; Won Kim, MD; Robert Motzer, MD; Elizabeth R. Plimack, MD, MS; and Brian Rini, MD, FACP.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.